At a glance

What is semax?

Semax is a synthetic seven-amino acid peptide based on a fragment of ACTH (adrenocorticotropic hormone), with added amino acids for stability. It was developed by Russian research institutes and is approved in Russia for stroke and cognitive and neurological conditions. Outside Russia it is sold through wellness and "research peptide" channels for cognition and neuroprotection, and it is not an approved medicine in the United States.

How does it work?

Semax is proposed to act as a nootropic and neuroprotectant by increasing levels of nerve-growth signals such as BDNF and NGF and modulating brain chemical systems. These effects are reported mainly in animal and laboratory studies¹. This describes the proposed mechanism, separate from demonstrated benefit in people.

Is it FDA-approved?

No. Semax is not approved by the FDA. As neutral regulatory facts: it is approved in Russia for stroke and cognitive indications; and in July 2026 the FDA's Pharmacy Compounding Advisory Committee gave semax a non-binding favorable advisory vote toward allowing it to be compounded under 503A, while FDA staff opposed it citing insufficient evidence². An advisory vote is only a recommendation; it does not make semax approved, and FDA rulemaking would still be required.

What does the research show?

There is some human evidence, but of limited quality. Russian studies have reported use in stroke, transient ischemic attack, cognitive disorders, and optic conditions, but the trials are generally:

• Small
• Methodologically weak
• Single-country
• Often developer-affiliated, with little independent replication

An analytical review³ notes these peptides have not completed clinical trials to Western standards. The evidence does not establish efficacy by those standards.

What is the difference between semax and selank?

Semax and selank are both synthetic seven-amino acid peptides developed by Russian research institutes, and the main difference is the natural molecule each is based on and the use each is approved for in Russia, as the table shows:

Both mechanism descriptions come mainly from animal and laboratory work, and neither has been shown to produce a benefit in people.

Neither peptide is FDA-approved. An advisory vote is only a recommendation, and it does not make semax approved.

The human evidence for both is limited in the same way: small, mostly Russian studies, often run by the developing institutions and not independently replicated. An analytical review³ notes that such peptides have not completed clinical trials to Western regulatory standards. The evidence does not establish that either one works or that one works better than the other.

Frequently asked questions

Is Semax FDA-approved?

No. As of September 2026, Semax is not FDA-approved for any indication in the United States. Semax is not eligible for 503A compounding. Its registration as a drug in Russia⁵ does not constitute FDA approval or equivalence.

What indications has Semax been studied for in Russia?

In the Russian clinical context, Semax has been studied in ischemic stroke rehabilitation⁶, chronic cerebrovascular insufficiency⁷, and optic nerve disease⁸. These are research-context indications in a non-US jurisdiction; they do not constitute FDA approval, and Semax has no FDA-approved indication in the United States.

What are the side effects of Semax?

Human safety data are thin: most published Semax studies did not report side effects, and there is not enough clinical information⁵ to characterize its safety profile. One report in FDA's adverse event database describes eye pain and burning after Semax nasal drops bought online, and possible anti-clotting effects described in one study raise a theoretical bleeding concern. Long-term safety data and independent Western pharmacovigilance data are not available; this limits the completeness of the known side effect profile. Any new or persistent symptom during a course should prompt contact with a clinician.

How does Semax work at the molecular level?

In rat studies, Semax raised BDNF and NGF gene activity⁴ in the brain's cortex after an induced stroke. BDNF supports neuronal survival and synaptic plasticity; its upregulation is the mechanism most closely linked to the effects reported in the published Russian literature. In rodents, Semax also boosted serotonin activity and amplified amphetamine-driven dopamine release⁹. A small resting-state fMRI study¹⁰ of 24 healthy volunteers found a larger default mode network subcomponent after intranasal Semax than after placebo, providing neuroimaging-level evidence of CNS activity.

Can you get Semax without a prescription?

Not through a lawful US pharmacy pathway. Semax is not FDA-approved, is not eligible for 503A compounding as of September 2026, and is not available over the counter. Obtaining Semax from unregulated research chemical sources carries unknown safety risks related to formulation quality and sterility.

What is the evidence quality for Semax?

The evidence base is best described as geographically and linguistically isolated. The most rigorous human data come from Russian clinical trials, primarily stroke trials , including a 1997 comparative study in acute ischemic stroke¹¹ of 110 patients (30 Semax-treated vs 80 controls) and a 2018 study of 110 post-stroke patients⁶ (two 10-day courses at 6,000 mcg/day). These trials are published in peer-reviewed journals, some indexed on PubMed, but they originate from a single national research ecosystem and have not been independently replicated in Western trials. Mechanistic data from genomic, transcriptomic, and proteomic studies describe a proposed molecular basis for the reported effects. The honest summary is that Semax has some published human clinical data, but less independent validation than would be required for FDA approval.

Are peptides legal in 2026?

Legality depends on the specific compound and the pathway through which it is accessed. As of September 2026, Semax is not eligible for 503A compounding, because it is not on the 503A bulks list or in Category 1¹². It is not FDA-approved, not available over the counter, and not available as a mass-produced pharmaceutical in the United States. FDA's advisory committee voted 8-5 on July 24, 2026² to recommend adding it, but that vote is non-binding. The broader question of peptide legality reflects ongoing FDA regulatory activity; individuals with specific questions about a compound's current regulatory status should consult a provider or regulatory counsel familiar with compounding law.

More for brain & sleep